Help us investigate a drug for people with Alzheimer’s disease

Research suggests that a cause of Alzheimer’s disease (AD) may be an abnormal build-up of a protein in the brain called amyloid beta. We are conducting the ENVISION study to confirm if this study drug that has been designed to reduce this build-up can help people with Mild Cognitive Impairment (MCI) due to AD or mild AD dementia compared to placebo.

Please take this flyer for more information.
Do you have MCI due to AD or mild AD dementia?

- Are you aged 60 to 85?
- If so, you may be able to participate in a clinical study called ENVISION

About the study

If you decide to join and are eligible, the ENVISION study will last for up to approximately 130 weeks (2 and a half years), including an 8-week screening period (to determine your eligibility), 104-week (2-year) treatment period and an 18-week follow-up period. During the treatment period, all participants will receive either the study drug or a placebo (a substance that looks the same as the study drug but contains no active ingredients). If you decide to join the ENVISION study, you will need to visit a study clinic approximately 40 times so that we can monitor your general health and condition with health assessments such as blood tests, brain MRI scans, neurological examinations, urine tests and vital signs. You will also have up to eight follow-up phone calls.

Is there anything else I need to know?

Participation in the ENVISION study is entirely voluntary. You have the right to leave at any time, without impact on your usual healthcare or any penalty. We would just ask you to visit the study clinic for a final round of assessments. Study treatment and health assessments will be provided to you at no cost, and you may be reimbursed for travel expenses. You do not need to have health insurance to participate.

To learn more about this study, please contact the study team. We will be more than happy to answer your questions and tell you more about this important research.

For more information about clinical trials, please visit the About Clinical Trials section on BiogenTrialLink.com